GLP-1 Side Effects & Controversies

Patients regain most weight after stopping the drug

Multiple studies confirm 50–70% weight regain within 1–2 years of stopping. This raises the question: is this a lifelong medication? The cost and side effect burden of lifetime use is significant. Critics argue GLP-1 companies benefit from creating permanent customers.

GLP-1 drugs cause significant muscle loss, not just fat loss

Up to 25–40% of weight lost on GLP-1 drugs is muscle, not fat. In older adults, this muscle loss (sarcopenia) can increase fall risk, weaken immune function, and worsen long-term metabolic health. The drug's label does not warn about this prominently.

GLP-1 drugs may cause thyroid cancer

The FDA black box warning is based on rodent studies where doses were much higher than human doses. Human epidemiological data has not confirmed increased papillary or follicular thyroid cancer. Medullary thyroid cancer risk in humans remains under study. Currently contraindicated if you have personal or family history of MTC.

Unregulated compounded GLP-1 drugs are flooding the market globally

During global shortages of Ozempic and Wegovy, compounding pharmacies began making semaglutide copies. The FDA has found hundreds of adverse events and some deaths linked to compounded products. In India, the generic market launched after patent expiry is regulated by CDSCO, but the quality gap between brands varies significantly.

GLP-1 drugs being prescribed without proper medical supervision in India

The Indian Medical Association (IMA) raised concerns in early 2026 about GLP-1 drugs being prescribed by non-specialists and even dispensed without prescriptions. The Ministry of Health issued guidance in April 2026 confirming GLP-1 drugs are prescription-only and should be prescribed only by endocrinologists for appropriate patients.

GLP-1 drugs are out of reach for most Indians despite being made in India

Even with generics at ₹325/week (₹1,290/month), long-term GLP-1 use costs ₹15,500+ per year — unaffordable for most Indians. Branded versions cost ₹60,000–1,70,000 per year. No health insurance in India covers GLP-1 for obesity. The drugs are largely accessible only to upper-middle-class urban patients.

Do GLP-1 drugs make bariatric surgery obsolete?

GLP-1 drugs achieve 15–22% weight loss vs 25–35% for bariatric surgery. Surgery is a one-time cost vs lifetime drug cost. Surgery has no weight regain issue. However, GLP-1 drugs are non-invasive and have fewer immediate risks. For patients with BMI 35–40, GLP-1 may be a valid alternative. For BMI 40+, surgery still has superior outcomes.